Results of POUT A phase III randomised trial of peri-operative chemotherapy versus surveillance in upper tract urothelial cancer (UTUC)

Abiraterone acetate (AA) + Prednisolone (P) for metastatic Castration-Resistant Prostate Cancer (mCRPC) with early progression or no-response to Androgen Deprivation Therapy (ADT); Final analysis

The PROSPER trial: chemotherapy-related endpoints in patients with nonmetastatic castration-resistant prostate cancer treated with enzalutamide

Interim results from PURE-01: a phase 2, open-label study of neoadjuvant pembrolizumab (pembro) before radical cystectomy for muscle-invasive urothelial bladder carcinoma (MIUC)

Prostate-Specific Antigen (PSA) Outcomes in Patients (pts) With Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC) Treated With Apalutamide (APA): Results From Phase 3 SPARTAN Study

Neoadjuvant Enzalutamide and Androgen Deprivation in High-Risk Prostate Cancer: Initial Imaging and Surgical Findings from a Phase II Clinical Trial

Sipuleucel-T (sip-T) with enzalutamide (enz) (STRIDE): clinical outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) by baseline (BL) prostate-specific antigen (PSA) quartiles

Sipuleucel-T immunotherapy for castrate-resistant prostate cancer modulates soluble B7-H3: a novel mechanism of action.

2-Year Follow-up of Radium-223 Re-treatment in an International, Open-Label, Phase 1/2 Study in Patients With Castration-Resistant Prostate Cancer and Bone Metastases

Impact of enzalutamide on pain and health-related quality of life in men with non-metastatic castration-resistant prostate cancer: PROSPER study results

Patient Reported Outcomes (PROs) in SPARTAN, a Phase 3, Double-Blind, Randomized Study of Apalutamide (APA) Plus Androgen Deprivation Therapy (ADT) vs Placebo Plus ADT in Men With Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC)

B cell concentration in high risk prostate cancer specimens after neoadjuvant rituximab

Clinical Characteristics Associated With Early Progression or Long-Term Response From the Phase II IMvigor210 Study: Atezolizumab in Locally Advanced or Metastatic Urothelial Carcinoma

Impact of positron emission tomography with 18F-fluciclovine on management of patients with suspected recurrence of prostate cancer: results from the LOCATE trial

Four-year follow-up of a phase-3 prospective randomized trial of vascular-targeted phototherapy versus active surveillance for low-risk prostate cancer